21 results
ARS
2022 FY
PNT
POINT Biopharma Global Inc.
1 May 23
Annual report to shareholders
1:52pm
, and Director Independence 101 Item 14. Principal Accounting Fees and Services 101 Part IV 102 Item 15. Exhibits, Financial Statement Schedules 102 Item 16
8-K
EX-1.1
PNT
POINT Biopharma Global Inc.
14 Sep 22
POINT Biopharma Prices Public Offering of Common Stock
4:14pm
) Auditor Independence. Armanino LLP, who have certified certain financial statements of the Company and its consolidated subsidiaries … and Related Transactions, and Director Independence”, insofar as they purport to summarize the provisions of the laws and documents referred to therein
424B3
PNT
POINT Biopharma Global Inc.
11 Jul 22
Prospectus supplement
4:32pm
. Certain Relationships and Related Transactions, and Director Independence” and our subsequent SEC filings incorporated by reference
POS AM
7ssy04502w
1 Jul 22
Prospectus update (post-effective amendment)
4:17pm
S-3
EX-1.2
57s164
1 Jul 22
Shelf registration
4:13pm
DEF 14A
dt5ouqj45b9gcj29
28 Apr 22
Definitive proxy
8:36am
424B3
exc7hqlhiy65
31 Mar 22
Prospectus supplement
11:42am
POS AM
521obmxmcub3gple
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
424B3
f811cblo7p9
5 Aug 21
Prospectus supplement
4:26pm
8-K
thj64dwpyk1y hi10
1 Jul 21
Unaudited pro forma condensed combined financial statements
12:00am
10-K
ajgo 5rf9fv9bq
5 Mar 21
Annual report
8:13am
424B4
lerzh3f6rk94vd
9 Jul 20
Prospectus supplement with pricing info
4:46pm
S-1
ut32aqyacwerdw
15 Jun 20
IPO registration
5:28pm